StockData
Heron Therapeutics, Inc. logo

Heron Therapeutics, Inc. (HRTX) stock

HRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$0.28−0.00 (-0.74%)

Close on Nov 17, 2026Market cap $53.58MP/E –Yield –

Earnings

Heron Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 25, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$35.30M
-7.6% on a year earlier
EPS, Q3 FY2026
-$0.03
Latest guidance
Reaffirmed
May 11, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of Heron Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 25, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 9, 2026before the open$35.30M-7.6%-$0.03Release
Q2 FY2026ended Jun 30, 2026Aug 10, 2026before the open$37.70M+1.3%-$0.03Release
Q1 FY2026ended Mar 31, 2026May 11, 2026before the open$34.70M-10.8%-$0.04Release
Q4 FY2025ended Dec 31, 2025Feb 26, 2026before the open$40.59M–-$0.02Release
Q3 FY2025ended Sep 30, 2025Nov 4, 2025before the open$38.20M+16.4%–Release
Q2 FY2025ended Jun 30, 2025Aug 8, 2025before the open$37.20M+3.3%–Release
Q1 FY2025ended Mar 31, 2025May 6, 2025before the open$38.90M+12.1%$0.01Release
Q4 FY2024ended Dec 31, 2024Feb 27, 2025before the open–––Release
Q3 FY2024ended Sep 30, 2024Nov 12, 2024before the open$32.81M+4.4%-$0.03Release
Q2 FY2024ended Jun 30, 2024Aug 6, 2024during market hours$36.00M+13.3%-$0.06Release
Q1 FY2024ended Mar 31, 2024May 7, 2024before the open$34.70M+17.2%-$0.02Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Heron Therapeutics's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Net RevenueGAAPFY2026$173.00M – $183.00M–NewMay 11, 2026
Net RevenueFY2026$173.00M – $183.00M–NewFeb 26, 2026
Adjusted EBITDAnon-GAAPFY2026$10.00M – $20.00M$10.00M – $20.00MReaffirmedMay 11, 2026

Guidance vs results

The last range Heron Therapeutics gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$153.00M – $163.00M$154.89MΣ4QWithin range
Q4 FY2022Revenue growth+30% – +40%+44.93%Above range
Q3 FY2022Revenue growth+40% – +50%+14.66%Below range
Q2 FY2022Revenue$22.00M – $23.00M$27.60MAbove range
Q1 FY2022Revenue$20.00M – $22.00M$23.50MAbove range
Q4 FY2021Revenue$20.00M – $22.00M$20.70MWithin range

Guidance history

Every forecast Heron Therapeutics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
May 11, 2026Adjusted EBITDAFY2026$10.00M – $20.00MReaffirmed
May 11, 2026Net RevenueFY2026$173.00M – $183.00MNew
Feb 26, 2026Adjusted EBITDAFY2026$10.00M – $20.00MNew
Feb 26, 2026Net RevenueFY2026$173.00M – $183.00MNew
Nov 4, 2025Adjusted EBITDAFY2025$9.00M – $13.00MNew
Nov 4, 2025Net RevenueFY2025$153.00M – $163.00MNew
Aug 8, 2025Adjusted EBITDAFY2025$9.00M – $13.00MRaised
Aug 8, 2025Net RevenueFY2025$153.00M – $163.00MReaffirmed
May 6, 2025Adjusted EBITDAFY2025$4.00M – $12.00MNew
May 6, 2025Net RevenueFY2025$153.00M – $163.00MNew
Nov 12, 2024Adjusted EBITDAFY2024$2.00M – $5.00MRaised
Nov 12, 2024Adjusted Operating ExpensesFY2024$101.00M – $105.00MLowered
Nov 12, 2024Net RevenueQ4 FY2024$37.00M – $43.00MNew
Nov 12, 2024Product Revenues, NetFY2024$140.00M – $146.00MNarrowed
Aug 6, 2024Adjusted EBITDAFY2024-$10.00M – $3.00MRaised
Aug 6, 2024Adjusted Operating ExpensesFY2024$107.00M – $111.00MLowered
Aug 6, 2024Product Revenues, NetFY2024$138.00M – $158.00MReaffirmed
May 7, 2024Adjusted EBITDAFY2024-$22.00M – $3.00MReaffirmed
May 7, 2024Adjusted Operating ExpensesFY2024$108.00M – $116.00MReaffirmed
May 7, 2024Product Revenues, NetFY2024$138.00M – $158.00MReaffirmed

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Heron Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. Results
  4. News
  5. Results
  6. Results
  7. Update
  8. Results
  9. Update
  10. News
  11. Results
  12. Results
  13. Results
  14. News
  15. Results

See a number that looks wrong?